Endogenous cannabinoids play important roles in a variety of functions in the mammalian brain, including the regulation reward-related information processing. The primary mechanism through which this is achieved is the presynaptic modulation of synaptic transmission. During reward-and reinforcement-related behavior dopamine levels increase in forebrain areas and this has recently been shown to be modulated by the endocannabinoid system. Therefore, understanding how endocannabinoids are mobilized to modulate synaptic inputs impinging on midbrain dopamine neurons is crucial to a complete understanding of the roles that these molecules play in reward behavior, drug abuse and addiction. Here we summarize the literature describing short-term and long-term regulation of afferent connections on dopamine neurons in the ventral tegmental area via endocannabinoid activation of cannabinoid CB1 receptors, and describe the mechanisms through which these molecules are released during reward-based behavior and exposure to abused drugs.
Introduction
Midbrain dopamine (DA) neurons are central components of the brain reward system. DA neurons fire in tonic pacemaker or phasic/ burst modes, the latter of which signals reward prediction error; the discrepancy between expected reward and actual reward (Cohen et al., 2012; Schultz et al., 1997) . This reward-related phasic activity of DA neurons is sufficient to support reinforcement learning, most likely by triggering long-term modification of synaptic connections (Glimcher, 2011; Steinberg et al., 2013) . All addictive drugs affect the brain's reward circuitry by enhancing DA levels in the nucleus accumbens (NAc), which is a primary target of DA neurons in the ventral tegmental area (VTA) (Gardner, 2011) . The endogenous cannabinoid (eCB) system is increasingly seen to play an important role in modulating rewardrelated changes of DA levels in the NAc and other forebrain targets to thereby regulate addictive behaviors (Melis and Pistis, 2012; Oleson et al., 2012) .
Endocannabinoid function in the CNS
All eCBs identified to date are lipid molecules. Although there are many eCBs that have been identified, in the context of the present review we refer to only those that act as agonists at the cannabinoid receptor type 1 (CB1R) cloned by Matsuda et al. (1990) . Endocannabinoids are released by neurons during heightened activity and interact with CB1Rs expressed throughout the CNS, where they inhibit the release of neurotransmitters such as GABA and glutamate (Alger, 2002; Melis et al., 2004b; Riegel and Lupica, 2004) . This form of eCB release is said to be "on demand" because it occurs when neuronal activity is high, and depends upon the influx of Ca 2+ (Bisogno et al., 1997; Di Marzo et al., 1994) . Furthermore, activity-dependent release of eCBs generally occurs in postsynaptic neurons whereas CB1Rs are most-often located on axon terminals. Therefore, eCBs are said to act in a "retrograde" manner to regulate neurotransmitter release. The transient eCB-mediated inhibition of neurotransmitter release has been labeled depolarization-induced suppression of "inhibition" Abbreviations: 2-AG, 2-arachidonoylglycerol; BAPTA, 1,2-bis(2-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid; cAMP, cyclic adenosine monophosphate; CB1, cannabinoid receptor type 1; CNS, central nervous system; DA, dopamine; DAG, diacylglycerol; DGLα, diacylglycerol lipase-α; DSE, depolarization-induced suppression of excitation; DSI, depolarization-induced suppression of inhibition; eCB, endogenous cannabinoid/ endocannabinoid; EPSCs, excitatory postsynaptic currents; ERK, extracellular signal regulated kinase; GABA, gamma-aminobutyric acid; GPCRs, G protein-coupled receptors; I-LTD, inhibitory LTD; IP3, inositol triphosphate; IPSCs, inhibitory postsynaptic current; LTD, long-term depression; LTP, long-term potentiation; mAChR, muscarinic acetylcholine receptors; MAGL, monoacylglycerol lipase; mGluRI, group I metabotropic glutamate receptors; NAc, nucleus accumbens; NT1R, type 1 neurotensin receptors; PIP2, phosphatidylinositol 4,5-bisphosphate; PKA, protein kinase A; PLC-β, phospholipase C-β; S k , small conductance calcium-sensitive potassium channels; THL, tetrahydrolipostatin; VTA, ventral tegmental area.
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